Cargando…

Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients

Germline and somatic mutations play a crucial role in breast cancer (BC), driving the initiation, progression, response to therapy and outcome of the disease. Hormonal therapy is limited to patients with tumors expressing steroid hormone receptors, such as estrogen receptor (ER), nevertheless resist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Griseri, Paola, Garrone, Ornella, Lo Sardo, Alessandra, Monteverde, Martino, Rusmini, Marta, Tonissi, Federica, Merlano, Marco, Bruzzi, Paolo, Lo Nigro, Cristiana, Ceccherini, Isabella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041993/ https://www.ncbi.nlm.nih.gov/pubmed/27034161 http://dx.doi.org/10.18632/oncotarget.8417

Ejemplares similares

RET in breast cancer: pathogenic implications and mechanisms of drug resistance
por: Lo Nigro, Cristiana, et al.
Publicado: (2019)

Induction of RET Dependent and Independent Pro-Inflammatory Programs in Human Peripheral Blood Mononuclear Cells from Hirschsprung Patients
por: Rusmini, Marta, et al.
Publicado: (2013)

Correction: Induction of RET Dependent and Independent Pro-Inflammatory Programs in Human Peripheral Blood Mononuclear Cells from Hirschsprung Patients
por: Rusmini, Marta, et al.
Publicado: (2013)

The Role of Cytokinome in the HNSCC Tumor Microenvironment: A Narrative Review and Our Experience
por: Denaro, Nerina, et al.
Publicado: (2022)

Circulating Cytokines in Metastatic Breast Cancer Patients Select Different Prognostic Groups and Patients Who Might Benefit from Treatment beyond Progression
por: Paccagnella, Matteo, et al.
Publicado: (2022)

Methylation of the calcium channel regulatory subunit α2δ-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas
por: Palmieri, C, et al.
Publicado: (2012)

Telomeric repeat-binding factor 2: a marker for survival and anti-EGFR efficacy in oral carcinoma
por: Benhamou, Yordan, et al.
Publicado: (2016)

Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse
por: Palmieri, C, et al.
Publicado: (2012)

Long noncoding RNAs as regulators of cancer immunity
por: Denaro, Nerina, et al.
Publicado: (2018)

Further Understanding of the Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: Implications for Prognosis
por: Denaro, Nerina, et al.
Publicado: (2021)

Incidence of cetuximab-related infusion reaction in head and neck cancer patients: may we predict it?
por: Merlano, Marco C, et al.
Publicado: (2018)

Head and neck cancer: improving outcomes with a multidisciplinary approach
por: Lo Nigro, Cristiana, et al.
Publicado: (2017)

Immune-related response criteria: light and shadows
por: Merlano, Marco, et al.
Publicado: (2016)

Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study
por: Garrone, Ornella, et al.
Publicado: (2020)

Incorporating prior biological information in linkage studies increases power and limits multiple testing
por: Lantieri, Francesca, et al.
Publicado: (2007)

The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer
por: Denaro, Nerina, et al.
Publicado: (2013)

RET signaling pathway and RET inhibitors in human cancer
por: Regua, Angelina T., et al.
Publicado: (2022)

Concerted epigenetic signatures inheritance at PcG targets through replication
por: Lanzuolo, Chiara, et al.
Publicado: (2012)

High frequency of complex TP53 mutations in CNS metastases from breast cancer
por: Lo Nigro, C, et al.
Publicado: (2012)

How I treat squamous ENT cancer
por: Merlano, Marco Carlo, et al.
Publicado: (2019)

Heterogeneity of colon cancer: from bench to bedside
por: Merlano, Marco C, et al.
Publicado: (2017)

PcG Complexes Set the Stage for Epigenetic Inheritance of Gene Silencing in Early S Phase before Replication
por: Lanzuolo, Chiara, et al.
Publicado: (2011)

Germ Line Mutations of the ret Proto‐oncogene in Japanese Patients with Multiple Endocrine Neoplasia Type 2A and Type 2B
por: Maruyama, Shoichi, et al.
Publicado: (1994)

Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies
por: Guyot, Mélanie, et al.
Publicado: (2016)

NT5E CpG island methylation is a favourable breast cancer biomarker
por: Lo Nigro, C, et al.
Publicado: (2012)

Unusual Fatal Outcome Following Administration of a Combination of anti-PD1 and anti-CTLA4 in Metastatic Renal Cell Carcinoma: Liver Toxicity Case Report and a Literature Review
por: Denaro, Nerina, et al.
Publicado: (2021)

Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer
por: O'Leary, K, et al.
Publicado: (2015)

NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity
por: Wang, H, et al.
Publicado: (2012)

Exploration of Tools for the Interpretation of Human Non-Coding Variants
por: Tabarini, Nicole, et al.
Publicado: (2022)

Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib
por: Ricci, Vincenzo, et al.
Publicado: (2020)

c-RET Molecule in Malignant Melanoma from Oncogenic RET-Carrying Transgenic Mice and Human Cell Lines
por: Ohshima, Yuichiro, et al.
Publicado: (2010)

Thrombotic Events during Lenvatinib Treatment: A Single Institution Experience
por: Denaro, Nerina, et al.
Publicado: (2022)

Melatonin and Hippo Pathway: Is There Existing Cross-Talk?
por: Lo Sardo, Federica, et al.
Publicado: (2017)

Precision therapy for RET-altered cancers with RET inhibitors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

The Role of p53 and MDM2 in Head and Neck Cancer
por: Denaro, N., et al.
Publicado: (2011)

Knowing the tumour microenvironment to optimise immunotherapy
por: MERLANO, M.C., et al.
Publicado: (2019)

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
por: Solomon, Benjamin J., et al.
Publicado: (2020)

Ret-dependent and Ret-independent mechanisms of Gfl-induced sensitization
por: Schmutzler, Brian S, et al.
Publicado: (2011)

Selective RET kinase inhibition for patients with RET-altered cancers
por: Subbiah, V, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c1mlltdv2390r3l7bgf9dgnhe2